TNFSF10 and breast carcinoma: Interestingly, in certain breast cancer cell lines (i.e., MCF7 and HCC1954) and in the lung adenocarcinoma cell line A549, the upregulation of TRAIL was substantially high, ranging from 50-fold to greater than 100-fold higher than that in other breast cancer lines (e.g., in BT549, it was 8-fold higher) and other cancer lines (e.g., in liver hepatocellular carcinoma, HepG2, it was 34-fold higher).